Dalbavancin via Intravenous Administration — Competitive Intelligence Brief

Dalbavancin via Intravenous Administration (Dalbavancin via Intravenous Administration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipoglycopeptide antibiotic. Area: Infectious Disease.

marketed Lipoglycopeptide antibiotic D-Ala-D-Ala peptidoglycan precursors Infectious Disease Small molecule

Target snapshot

Dalbavancin via Intravenous Administration (Dalbavancin via Intravenous Administration) — University of Colorado, Denver. Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dalbavancin via Intravenous Administration TARGET	Dalbavancin via Intravenous Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors
Cefazolin / Vancomycin	Cefazolin / Vancomycin	University of Cincinnati	marketed	Beta-lactam antibiotic / Glycopeptide antibiotic	Penicillin-binding proteins / D-Ala-D-Ala peptidoglycan precursors
IV Dalbavancin	IV Dalbavancin	Durata Therapeutics Inc., an affiliate of Allergan plc	phase 3	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors
Dalbavancin via Intraperitoneal Administration	Dalbavancin via Intraperitoneal Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Oritavancin Injection	Oritavancin Injection	University of Pennsylvania	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II
Single-Dose IV Oritavancin Diphosphate	Single-Dose IV Oritavancin Diphosphate	Melinta Therapeutics, Inc.	phase 3	Lipoglycopeptide antibiotic	Lipid II
Dalbavancin administration	Dalbavancin administration	Assistance Publique - Hôpitaux de Paris	phase 3	Lipoglycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipoglycopeptide antibiotic class)

1. University of Colorado, Denver · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Durata Therapeutics Inc., an affiliate of Allergan plc · 1 drug in this class
4. Melinta Therapeutics, Inc. · 1 drug in this class
5. University of Pennsylvania · 1 drug in this class